Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography

Sci Rep. 2019 Dec 17;9(1):19240. doi: 10.1038/s41598-019-55871-8.

Abstract

The advent of anti-vascular endothelial growth factor (VEGF) therapies has remarkably improved the functional outcomes of neovascular age-related macular degeneration (nAMD) patients. However, there are guidelines on how to start treatment, the guidelines for discontinuing treatment are not yet clear. In this respect, the treat-extend-stop (TES) protocol have showed us the possibility of discontinuing treatment. In this study, we tried to investigate optical coherence tomography angiography (OCTA) biomarkers related to recurrence of neovascular activity in eyes with nAMD undergoing treatment using TES protocol. A total of 134 eyes with nAMD were divided into two groups (stop, non-stop) depending on whether they met criteria for stopping anti-VEGF treatment. Quantitative and qualitative OCTA parameters including the morphologic pattern of choroidal neovascularization (CNV) were compared between groups. Of these, 44 eyes (32.8%) were in the stop group and 90 eyes (67.2%) were in the non-stop group. In multivariate regression analysis, closed-circuit pattern of CNV and the presence of peripheral loop were associated with the non-stop group (all p < 0.001). Our results imply that the morphologic appearance of CNV on OCTA after anti-VEGF treatment may be a useful biomarker to predict weaning from treatment.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage*
  • Choroidal Neovascularization* / diagnostic imaging
  • Choroidal Neovascularization* / drug therapy
  • Choroidal Neovascularization* / metabolism
  • Female
  • Humans
  • Macular Degeneration* / diagnostic imaging
  • Macular Degeneration* / drug therapy
  • Macular Degeneration* / metabolism
  • Male
  • Middle Aged
  • Retrospective Studies
  • Tomography, Optical Coherence*

Substances

  • Angiogenesis Inhibitors